Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Breast Cancer, Prostate Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2016 |
| End Date: | February 2017 |
Gene Expression Control Using Micro-Trace Element Compounds During C.A.M. and Conventional Cancer Protocols
RATIONALE: Natural supplements and a special diet may help rid the body of estrogen and
testosterone and may slow the growth of tumor cells.
PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through
laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using
natural supplements and a special diet work, extemporaneous and environmental (man-made)
hormones, hormone impacting compounds and hormone-mimicking compounds that are made outside
the body, found in manufactured products or in-taken to the body of cancer patients through
life-style, environmental or consumption products. Patients with early-stage or remission
stage prostate cancer, breast cancer, or uterine cancer have a much greater sensitivity to
these extemporaneous hormonal or hormonal influencing compounds.
testosterone and may slow the growth of tumor cells.
PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through
laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using
natural supplements and a special diet work, extemporaneous and environmental (man-made)
hormones, hormone impacting compounds and hormone-mimicking compounds that are made outside
the body, found in manufactured products or in-taken to the body of cancer patients through
life-style, environmental or consumption products. Patients with early-stage or remission
stage prostate cancer, breast cancer, or uterine cancer have a much greater sensitivity to
these extemporaneous hormonal or hormonal influencing compounds.
OBJECTIVES:
To utilize multiple naturally-occurring micro-trace element compounds to sequester exogenous
estrogens, estrogen-mimicking and estrogen-influencing compounds, from multiple sources,
including environmental and metabolic sources, and eliminate them from the body prior to
influencing prostate, breast, and uterine cancer pathways in cancer patients and cancer
patients in remission.
To utilize specific naturally-occurring flavonoids to suppress proliferation-stimulating
activities induced by normal metabolism and environmental estrogen, estrogen-mimicking,
estrogen-influencing and testosterone-type compounds.
To utilize DPPH radical-scavenging activity to reduce secondary bonding of TMPRSS2-ERG
fusing and negative-bonded environmental estrogen.
To utilize endocrine system related immune response compounds as a means to help control
and/or chemically influence/impact extemporaneous environmental and accumulated life-style
estrogen, estrogen-mimicking, estrogen-influencing and testosterone-type compounds for
preventing or controlling recurrence of breast, uterine or prostate cancers; hormonally
influenced cancers.
To utilize a full diet of specifically grown inclusion produce to maintain normal metabolic
function.
BACKGROUND DATA:
Laboratory analytical instrumentation has improved the ability to measure, track and analyze
extemporaneous environmental and accumulated life-style estrogen, estrogen-mimicking,
estrogen-influencing and testosterone-type compounds.
The initial data accumulation of spheres of chemical influence from human hormonal,
hormonal-mimicking or hormonal-influencing compounds has radically changed since the
beginning of this Phase 1 clinical trial.
For example, endocrine disruptor compounds (EDCs) also commonly called hormonally active
agents (1) have been shown to have strong estrogenic-type effects on the body of both female
and male cancer patients. Whereas xenoestrogenic compounds, example PCBs, BPA, DDT and
phthalates, have been found to have direct body influence, other hormonally-influencing
compounds, like nicotine and atrazine, are not as easily predictable in how they affect
existing and remission cancers.
The pharmacological actions of nicotine, for example, have been shown to impact hormonal and
growth factors and Marinucci et al (2) showed concretely that nicotine differently regulated
cell growth. With the work of Camargo, et al (3) the effect of nicotine on androgen
over-production was settled as factual. The tobacco industry has seemingly allowed the
connection of smoking and cancer to be investigated when the causal agent for the cancers
are limited to carcinogens found in "smoke." However, newer analyses show clearly that
nicotine itself, found in the cigarette smoke and today in e-cigarettes, as having an
influence on estrogen synthesis in the body as well as blocking monoxygenase control of
HMG-CoA Reductase and thereby control of oncogenic expression. The pathway is clear that
nicotine-induced sympathetic activation could account for also the increased thyroid hormone
secretion and as a result the nicotine-influenced estrogen metabolic pathway, resulting in
lower estrogen levels but higher androgen levels also affects TSH levels. Combined these two
factors, influenced by nicotine, show real biochemical pathway to both influencing benign
breast cancer and remission breast cancer to have a more androgen-influenced aggressive
behavior. The androgen influenced recurrence breast and prostate are less controllable by
any current level of pharmaceutical control method.
Raval (4) showed chemically that nicotine, not other compounds in "smoke," reduces
circulating estrogen. Therefore in the metabolic pathway, preventing the final metabolite,
estrogen, increases the precursor compounds, increasing circulating androgen. While
Holloway, et al, (5) showed that in utero exposure to nicotine had a demonstrable influence
of endocrine effect on placental development and corresponding (decrease) of fetomaternal
circulation.
Newer research, Bavarva, et al, (6) indicates that environmental impact and/or lifestyle
addictions, nicotine in this example, alter actual gene expression and, in and of itself,
can cause the genetic basis for induced cancer development.
EDCs, (endocrine disruptor/disrupting compounds), are found in multiple industry arenas. Due
to advances in detection techniques, endocrine disruption, known as far back as the early
1990s, was generally thought to be "specie-specific." However, newer research has found that
not to be the case.
On a worldwide scientific research basis, the triazine family of nitrogen containing
six-membered heterocyclic benzene aromatic ring compound herbicides are regarded as an
endocrine disrupting compound. Hayes (7) found significant sex gland aberrations and
gender-bending in amphibians exposed to varied levels of atrazine in field/natural
conditions that were then validated in laboratory conditions.
In 2007 the EPA found cause to suspect triazine/atrazine as having endocrine/hormonal impact
on developing children (8) but as atrazine is the number one selling herbicide in the USA,
pressure from the agricultural and chemical manufacturing industry keeps the product in the
marketplace.
Research by Mizota (9) clearly showing "atrazine exerts inflammatory activity through
activation of putative G(q/11)-coupled neurosteroid receptor and phospholipase C" then
allows for the atrazine-induced biochemical estrogen impacting pathway with altered
receptors of male versus female developmental hormonal response. More specifically;
progesterone receptor-modulation of atrazine-induced mast cell degranulation changes the
pathway of estrogen/ estriol, 17β-estradiol and progesterone creating an accumulation of
precursor compound, 17β-estradiol, and therefore the androgen precursor, without the final
product of the synthesis: estriol.
17β-estradiol has an extreme level of hormonal activity and as a result, when over-produced
or found in amounts not of specific ration to other estrogenic hormones, specifically
estriol (the down-stream product of 17β-estradiol synthesis) the result is a higher affinity
in receptors for 17β-estradiol instead of the lower DNA influencing compound estriol. This
bondage impairs G1, S, or G2 phases of DNA repair in the cell cycle and directly accelerates
the proliferation of DNA damaged cells, cancerous, in breast, uterine and ovarian organs.
(10) Due to the persistence of the triazine family of herbicides in soils and
ground/drinking water and its apparent impact on hormonal reactions, the EU banned
atrazine/triazine from use in any EU country. Further, atrazine residue on products imported
into the EU is also severely restricted.
Atrazine is found in virtually every USA woman's body, notably in breast and ovarian tissue.
It is found in more US state drinking water tests than any other pollutant. It is second in
usage to glyphosate on USA crop acres but, as it was in use decades before glyphosate, it is
higher in groundwater sampling as of 2011.
As a result of these newer levels of cellular research, extemporaneous influences on cancer,
notably hormonal cancers, are being found as having a crucial role in the continuing rate of
breast, prostate, uterine and ovarian cancers.
Negating these near-human and human-like EDCs and/or their influence on the body has, to
date, been overlooked as a therapy and under-emphasized as the course of action for cancer
treatments. This study both advances the roles EDCs play in hormonally controlled cancers
and the effect natural plant compounds, coupled with ultra-trace mineral/elemental
molecules, have in reducing or eliminating them from negative impact in the human body.
OUTLINE: Patients are randomized to 1 of 2 arms.
Arm I: Patients receive oral natural supplements comprising indole-3-carbinol, perillyl
alcohol, glucuronic acid, and flavonoids daily for 12 months. Patients also consume whole
foods comprising indole-3-carbinol and a diet that eliminates exogenous growth hormones.
Arm II: Patients do not receive natural supplements or consume whole foods or a special
diet.
Levels of compounds of interest are measured by inductively-coupled plasma mass
spectrometry, high performance liquid chromatography, gas chromatography, and
matrix-assisted laser desorption/ionization time of flight mass spectrometry.
After completion of study therapy, patients are followed periodically for 6 months and
monitored for a second 6 months period.
1. Krimsky S (December 2001). "An epistemological inquiry into the endocrine disruptor
thesis". Ann. N. Y. Acad. Sci. 948 (1): 130-42. doi:10.1111/j.1749-6632.2001.tb03994.x.
PMID 11795392.
2. Marinucci L, Bodo M, Balloni S, Locci P, Baroni T. "Sub-Toxic Nicotine Concentrations
Affect Extracellular Matrix and Growth Factor Signaling Gene Expressions in Human
Osteoblasts." J Cell Physiol. 2014 Apr 29. doi: 10.1002/jcp.24661. PMID: 24777817
3. Camargo IC, Leite GA, Pinto T, Ribeiro-Paes JT. "Histopathologycal findings in the
ovaries and uterus of albino female rats promoted by co-administration of synthetic
steroids and nicotine." Exp Toxicol Pathol. 2014 Jul;66(4):195-202. doi:
10.1016/j.etp.2014.01.005. Epub 2014 Feb 18. PMID: 24556002
4. Raval AP. "Nicotine addiction causes unique detrimental effects on women's brains." J
Addict Dis. 2011 Apr;30(2):149-58. doi: 10.1080/10550887.2011.554782. Review. PMID:
21491296
5. Holloway AC, Salomon A, Soares MJ, Garnier V, Raha S, Sergent F, Nicholson CJ, Feige
JJ, Benharouga M, Alfaidy N. "Characterization of the adverse effects of nicotine on
placental development: in vivo and in vitro studies." Am J Physiol Endocrinol Metab.
2014 Feb 15;306(4):E443-56. doi: 10.1152/ajpendo.00478.2013. Epub 2013 Dec 24. PMID:
24368670
6. Bavarva JH, Tae H, Settlage RE, Garner HR. "Characterizing the Genetic Basis for
Nicotine Induced Cancer Development: A Transcriptome Sequencing Study." PLoS One. 2013
Jun 18;8(6):e67252. Print 2013. PMID: 23825647
7. Hayes, Tyrone B.; Anderson, Lloyd L.; Beasley, Val R.; de Solla, Shane R.; Iguchi,
Taisen; et al. (2011). "Demasculinization and feminization of male gonads by atrazine:
Consistent effects across vertebrate classes". The Journal of Steroid Biochemistry and
Molecular Biology 127 (1-2): 64-73. doi:10.1016/j.jsbmb.2011.03.015. PMID 21419222
8. Atrazine: Chemical Summary. Toxicity and Exposure Assessment for Children's Health
(Report). U.S. Environmental Protection Agency. 4/24/2007
9. Mizota, K.; Ueda, H. (2006). "Endocrine Disrupting Chemical Atrazine Causes
Degranulation through Gq/11 Protein-Coupled Neurosteroid Receptor in Mast Cells".
Toxicological Sciences 90 (2): 362-8. doi:10.1093/toxsci/kfj087. PMID 16381660
10. Thomas, Christoforos; Strom A.; Lindberg K.; Gustafsson J. (22 June 2010). "Estrogen
receptor beta decreases survival of p53-defective cancer cells after DNA damage by
impairing G2/M checkpoint signaling". Breast Cancer Research and Treatment 127 (2):
417-427. doi:10.1007/s10549-010-1011-z. PMID 20623183
To utilize multiple naturally-occurring micro-trace element compounds to sequester exogenous
estrogens, estrogen-mimicking and estrogen-influencing compounds, from multiple sources,
including environmental and metabolic sources, and eliminate them from the body prior to
influencing prostate, breast, and uterine cancer pathways in cancer patients and cancer
patients in remission.
To utilize specific naturally-occurring flavonoids to suppress proliferation-stimulating
activities induced by normal metabolism and environmental estrogen, estrogen-mimicking,
estrogen-influencing and testosterone-type compounds.
To utilize DPPH radical-scavenging activity to reduce secondary bonding of TMPRSS2-ERG
fusing and negative-bonded environmental estrogen.
To utilize endocrine system related immune response compounds as a means to help control
and/or chemically influence/impact extemporaneous environmental and accumulated life-style
estrogen, estrogen-mimicking, estrogen-influencing and testosterone-type compounds for
preventing or controlling recurrence of breast, uterine or prostate cancers; hormonally
influenced cancers.
To utilize a full diet of specifically grown inclusion produce to maintain normal metabolic
function.
BACKGROUND DATA:
Laboratory analytical instrumentation has improved the ability to measure, track and analyze
extemporaneous environmental and accumulated life-style estrogen, estrogen-mimicking,
estrogen-influencing and testosterone-type compounds.
The initial data accumulation of spheres of chemical influence from human hormonal,
hormonal-mimicking or hormonal-influencing compounds has radically changed since the
beginning of this Phase 1 clinical trial.
For example, endocrine disruptor compounds (EDCs) also commonly called hormonally active
agents (1) have been shown to have strong estrogenic-type effects on the body of both female
and male cancer patients. Whereas xenoestrogenic compounds, example PCBs, BPA, DDT and
phthalates, have been found to have direct body influence, other hormonally-influencing
compounds, like nicotine and atrazine, are not as easily predictable in how they affect
existing and remission cancers.
The pharmacological actions of nicotine, for example, have been shown to impact hormonal and
growth factors and Marinucci et al (2) showed concretely that nicotine differently regulated
cell growth. With the work of Camargo, et al (3) the effect of nicotine on androgen
over-production was settled as factual. The tobacco industry has seemingly allowed the
connection of smoking and cancer to be investigated when the causal agent for the cancers
are limited to carcinogens found in "smoke." However, newer analyses show clearly that
nicotine itself, found in the cigarette smoke and today in e-cigarettes, as having an
influence on estrogen synthesis in the body as well as blocking monoxygenase control of
HMG-CoA Reductase and thereby control of oncogenic expression. The pathway is clear that
nicotine-induced sympathetic activation could account for also the increased thyroid hormone
secretion and as a result the nicotine-influenced estrogen metabolic pathway, resulting in
lower estrogen levels but higher androgen levels also affects TSH levels. Combined these two
factors, influenced by nicotine, show real biochemical pathway to both influencing benign
breast cancer and remission breast cancer to have a more androgen-influenced aggressive
behavior. The androgen influenced recurrence breast and prostate are less controllable by
any current level of pharmaceutical control method.
Raval (4) showed chemically that nicotine, not other compounds in "smoke," reduces
circulating estrogen. Therefore in the metabolic pathway, preventing the final metabolite,
estrogen, increases the precursor compounds, increasing circulating androgen. While
Holloway, et al, (5) showed that in utero exposure to nicotine had a demonstrable influence
of endocrine effect on placental development and corresponding (decrease) of fetomaternal
circulation.
Newer research, Bavarva, et al, (6) indicates that environmental impact and/or lifestyle
addictions, nicotine in this example, alter actual gene expression and, in and of itself,
can cause the genetic basis for induced cancer development.
EDCs, (endocrine disruptor/disrupting compounds), are found in multiple industry arenas. Due
to advances in detection techniques, endocrine disruption, known as far back as the early
1990s, was generally thought to be "specie-specific." However, newer research has found that
not to be the case.
On a worldwide scientific research basis, the triazine family of nitrogen containing
six-membered heterocyclic benzene aromatic ring compound herbicides are regarded as an
endocrine disrupting compound. Hayes (7) found significant sex gland aberrations and
gender-bending in amphibians exposed to varied levels of atrazine in field/natural
conditions that were then validated in laboratory conditions.
In 2007 the EPA found cause to suspect triazine/atrazine as having endocrine/hormonal impact
on developing children (8) but as atrazine is the number one selling herbicide in the USA,
pressure from the agricultural and chemical manufacturing industry keeps the product in the
marketplace.
Research by Mizota (9) clearly showing "atrazine exerts inflammatory activity through
activation of putative G(q/11)-coupled neurosteroid receptor and phospholipase C" then
allows for the atrazine-induced biochemical estrogen impacting pathway with altered
receptors of male versus female developmental hormonal response. More specifically;
progesterone receptor-modulation of atrazine-induced mast cell degranulation changes the
pathway of estrogen/ estriol, 17β-estradiol and progesterone creating an accumulation of
precursor compound, 17β-estradiol, and therefore the androgen precursor, without the final
product of the synthesis: estriol.
17β-estradiol has an extreme level of hormonal activity and as a result, when over-produced
or found in amounts not of specific ration to other estrogenic hormones, specifically
estriol (the down-stream product of 17β-estradiol synthesis) the result is a higher affinity
in receptors for 17β-estradiol instead of the lower DNA influencing compound estriol. This
bondage impairs G1, S, or G2 phases of DNA repair in the cell cycle and directly accelerates
the proliferation of DNA damaged cells, cancerous, in breast, uterine and ovarian organs.
(10) Due to the persistence of the triazine family of herbicides in soils and
ground/drinking water and its apparent impact on hormonal reactions, the EU banned
atrazine/triazine from use in any EU country. Further, atrazine residue on products imported
into the EU is also severely restricted.
Atrazine is found in virtually every USA woman's body, notably in breast and ovarian tissue.
It is found in more US state drinking water tests than any other pollutant. It is second in
usage to glyphosate on USA crop acres but, as it was in use decades before glyphosate, it is
higher in groundwater sampling as of 2011.
As a result of these newer levels of cellular research, extemporaneous influences on cancer,
notably hormonal cancers, are being found as having a crucial role in the continuing rate of
breast, prostate, uterine and ovarian cancers.
Negating these near-human and human-like EDCs and/or their influence on the body has, to
date, been overlooked as a therapy and under-emphasized as the course of action for cancer
treatments. This study both advances the roles EDCs play in hormonally controlled cancers
and the effect natural plant compounds, coupled with ultra-trace mineral/elemental
molecules, have in reducing or eliminating them from negative impact in the human body.
OUTLINE: Patients are randomized to 1 of 2 arms.
Arm I: Patients receive oral natural supplements comprising indole-3-carbinol, perillyl
alcohol, glucuronic acid, and flavonoids daily for 12 months. Patients also consume whole
foods comprising indole-3-carbinol and a diet that eliminates exogenous growth hormones.
Arm II: Patients do not receive natural supplements or consume whole foods or a special
diet.
Levels of compounds of interest are measured by inductively-coupled plasma mass
spectrometry, high performance liquid chromatography, gas chromatography, and
matrix-assisted laser desorption/ionization time of flight mass spectrometry.
After completion of study therapy, patients are followed periodically for 6 months and
monitored for a second 6 months period.
1. Krimsky S (December 2001). "An epistemological inquiry into the endocrine disruptor
thesis". Ann. N. Y. Acad. Sci. 948 (1): 130-42. doi:10.1111/j.1749-6632.2001.tb03994.x.
PMID 11795392.
2. Marinucci L, Bodo M, Balloni S, Locci P, Baroni T. "Sub-Toxic Nicotine Concentrations
Affect Extracellular Matrix and Growth Factor Signaling Gene Expressions in Human
Osteoblasts." J Cell Physiol. 2014 Apr 29. doi: 10.1002/jcp.24661. PMID: 24777817
3. Camargo IC, Leite GA, Pinto T, Ribeiro-Paes JT. "Histopathologycal findings in the
ovaries and uterus of albino female rats promoted by co-administration of synthetic
steroids and nicotine." Exp Toxicol Pathol. 2014 Jul;66(4):195-202. doi:
10.1016/j.etp.2014.01.005. Epub 2014 Feb 18. PMID: 24556002
4. Raval AP. "Nicotine addiction causes unique detrimental effects on women's brains." J
Addict Dis. 2011 Apr;30(2):149-58. doi: 10.1080/10550887.2011.554782. Review. PMID:
21491296
5. Holloway AC, Salomon A, Soares MJ, Garnier V, Raha S, Sergent F, Nicholson CJ, Feige
JJ, Benharouga M, Alfaidy N. "Characterization of the adverse effects of nicotine on
placental development: in vivo and in vitro studies." Am J Physiol Endocrinol Metab.
2014 Feb 15;306(4):E443-56. doi: 10.1152/ajpendo.00478.2013. Epub 2013 Dec 24. PMID:
24368670
6. Bavarva JH, Tae H, Settlage RE, Garner HR. "Characterizing the Genetic Basis for
Nicotine Induced Cancer Development: A Transcriptome Sequencing Study." PLoS One. 2013
Jun 18;8(6):e67252. Print 2013. PMID: 23825647
7. Hayes, Tyrone B.; Anderson, Lloyd L.; Beasley, Val R.; de Solla, Shane R.; Iguchi,
Taisen; et al. (2011). "Demasculinization and feminization of male gonads by atrazine:
Consistent effects across vertebrate classes". The Journal of Steroid Biochemistry and
Molecular Biology 127 (1-2): 64-73. doi:10.1016/j.jsbmb.2011.03.015. PMID 21419222
8. Atrazine: Chemical Summary. Toxicity and Exposure Assessment for Children's Health
(Report). U.S. Environmental Protection Agency. 4/24/2007
9. Mizota, K.; Ueda, H. (2006). "Endocrine Disrupting Chemical Atrazine Causes
Degranulation through Gq/11 Protein-Coupled Neurosteroid Receptor in Mast Cells".
Toxicological Sciences 90 (2): 362-8. doi:10.1093/toxsci/kfj087. PMID 16381660
10. Thomas, Christoforos; Strom A.; Lindberg K.; Gustafsson J. (22 June 2010). "Estrogen
receptor beta decreases survival of p53-defective cancer cells after DNA damage by
impairing G2/M checkpoint signaling". Breast Cancer Research and Treatment 127 (2):
417-427. doi:10.1007/s10549-010-1011-z. PMID 20623183
DISEASE CHARACTERISTICS:
- Diagnosis of prostate, breast, or uterine cancer
- Early-stage disease
- Currently waiting to initiate conventional therapy or radiotherapy OR receiving
concurrent conventional chemotherapy or radiation therapy
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior or concurrent chemotherapy or hormonal therapy for cancer allowed
We found this trial at
1
site
Click here to add this to my saved trials
